Korro Bio (KRRO) vs NovaBridge Biosciences (NBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
NovaBridge Biosciences (NBP) has outperformed Korro Bio (KRRO) over the past year, losing 68.6% versus a loss of 78.5%. Over five years, KRRO leads with a -97.0% price change compared with -97.9% for NBP. NovaBridge Biosciences is the larger company by market cap ($158.9 million vs $154.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | NBP |
|---|---|---|
| Share price | $10.49 | $1.37 |
| Market cap | $154.47M | $158.92M |
| 1-day change | +7.48% | -2.14% |
| YTD return | +30.96% | -65.58% |
| 1-year return | -78.49% | -68.65% |
| 5-year return | -97.05% | -97.92% |
| EPS (TTM) | $-10.62 | $-0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.89 | $6.79 |
| 52-week low | $5.20 | $1.31 |
| Distance from 52-week high | -81.23% | -79.82% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +92.56% | +556.93% |
| Average volume | 148.67K | 387.52K |
| Shares outstanding | 14.73M | 116.00M |
| Employees | 57 | 30 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Healthcare · Biotechnology · 57 employees
About NovaBridge Biosciences
NBP stock →NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology.
Healthcare · Biotechnology · 30 employees
KRRO vs NBP FAQ
Which is bigger, Korro Bio or NovaBridge Biosciences?
NovaBridge Biosciences (NBP) is larger, with a market capitalization of $158.92M compared with $154.47M for Korro Bio (KRRO).
Which stock has performed better over the past year, KRRO or NBP?
NBP returned -68.65% over the past 12 months, compared with -78.49% for KRRO (price return, excluding dividends). Past performance does not predict future results.
Are Korro Bio and NovaBridge Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.